Difference between revisions of "Prostate cancer with neuroendocrine differentiation"
Jump to navigation
Jump to search
(→IHC) |
|||
| (One intermediate revision by the same user not shown) | |||
| Line 16: | Line 16: | ||
==IHC== | ==IHC== | ||
*[[PSA]] typically negative in | *[[PSA]] typically negative in neuroendocrine carcinomas. | ||
==See also== | ==See also== | ||
*[[Prostate cancer]]. | *[[Prostate cancer]]. | ||
*[[Neuroendocrine carcinoma]]. | *[[Neuroendocrine carcinoma]]. | ||
*[[Paneth cell-like change of the prostate gland]]. | |||
==References== | ==References== | ||
Latest revision as of 22:47, 19 March 2018
Prostate cancer with neuroendocrine differentiation is a rare group of prostate cancers that is hypothesized to evolve in the context androgen deprivation therapy.[1]
Neuroendocrine carcinoma of the prostate redirect here.
General
- Treatment: platinum based therapy.
Subclassification
It is subclassified as per Epstein et al.:[1]
- Usual prostate adenocarcinoma with neuroendocrine differentiation.
- Adenocarcinoma with Paneth cell neuroendocrine differentiation.
- Carcinoid tumour of the prostate.
- Small cell carcinoma of the prostate gland.
- Large cell neuroendocrine carcinoma of the prostate.
- Mixed (small and/or large cell) neuroendocrine carcinoma-acinar adenocarcinoma.
IHC
- PSA typically negative in neuroendocrine carcinomas.
See also
References
- ↑ 1.0 1.1 Epstein, JI.; Amin, MB.; Beltran, H.; Lotan, TL.; Mosquera, JM.; Reuter, VE.; Robinson, BD.; Troncoso, P. et al. (Jun 2014). "Proposed morphologic classification of prostate cancer with neuroendocrine differentiation.". Am J Surg Pathol 38 (6): 756-67. doi:10.1097/PAS.0000000000000208. PMID 24705311.